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OAortic valve repair: Defining the patient population and timing
of the interventionRakesh M. Suri, MD, DPhil, and Hartzell V. Schaff, MDSee related article on pages 1913-20 in the
November 2014 issue.Unlike the scientific rationale justifying early mitral valve
repair for asymptomatic patients with severe degenerative
mitral regurgitation,1 a more stringent threshold limits the
recommendation for surgery in the setting of severe aortic
regurgitation (AR).2 This is in part due to the fact that aortic
valve replacement (AVR) is often performed rather than
valve repair. Current consensus statements recommend
earlier AVR in patients with asymptomatic severe AR
(ie, stage C) when ejection fraction is<50% (class I), at
the time of another cardiac surgical procedure (class I),
or when or left ventricular end systolic dimension is
>50 mm (class IIa). Caution is given that ‘‘.performance
of aortic valve (AV) repair should be concentrated in those
centers with proven expertise in the procedure.’’2
De Meester and colleagues3 analyzed 44 propensity-
matched patient pairs who underwent surgical correction
of severe AR by AV repair (mean age 65 years) versus
AVR (mean age 63 years) between 1995 and 2012. They
found similar early mortality (2% for repair vs 5% for
AVR; P ¼ .56) but better late survival after AV repair
than after AVR (87% vs 60%; P ¼ .007). Repair was an
independent predictor of improved late survival, but was
associated with a ‘‘slight’’ increase in reoperation rate at
9 years (8% vs 2%; P ¼ .35). The authors concluded that
‘‘AV repair significantly improves postoperative outcomes
. and whenever feasible, should probably be the preferred
mode of surgical correction.’’
Is this new?3-7 Amongst 331 patients (mean age 53 years)
who underwent elective AV repair for AR at the Mayo
Clinic, in-hospital mortality was 0.6% (2 out of 332
patients), and overall survival was 91% and 81% at 5 and
10 years, respectively. Patients with an ejection fraction
<50% and left ventricular end systolic dimension
>50 mm had significantly higher odds of late death (hazard
ratio, 3.46 [P<.001] and hazard ratio, 2.08 [P ¼ .036]).4From the Division of Cardiovascular Surgery, Mayo Clinic, Rochester, Minn.
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10 years, respectively. But when we specifically compared
outcomes of AV repair in patients with bicuspid aortic
valves to an age- and sex-matched cohort who had AVR
with heterograft bioprostheses, we found no significant
difference in 10-year survival (72% vs 79%; P ¼ .13) or
freedom from reoperation between groups (90% vs 98%
and 72% vs 64% in 5 and 10 years, respectively; P<.12).8
Are comparisons between the practices of aortic and
mitral valve repair legitimate? Recent advancements have
occurred in the understanding of AV cusp anatomy, echocar-
diographic predictors of AV repair success (based on cusp
dimensions and coaptation height), and AV repair tech-
niques.3,9-13 Despite this progress, the disciplines of aortic
and mitral valve repair may not be entirely analogous.
First, AV repair strategies remain heterogeneously applied
amongst surgeons and institutions. Second, whereas leaflet
tissue quality is less frequently a concern in patients with
degenerative mitral valve regurgitation (repair>98% at
experienced centers and reoperation<1%/y); aortic cusp
pliability, mobility, and calcification are less predictable
and all dramatically affect AV repair performance and
durability. Third, whereas excess leaflet tissue most often
exists in degenerative mitral valve disease, allowing
surgeons to trim, shape, and support valve leaflets, the
relative paucity of AV cusp tissue may at times preclude
the performance of AV repair, particularly in the presence
of cusp restriction, thickening, or fenestration. Fourth, the
frequency with which bicuspid AV variations are
encountered contribute to AV repair remaining a highly
technical and judgment-dependent procedure. Furthermore,
unlike a repaired mitral valve, a repaired bicuspid AV
remains at risk for late calcification and stenosis.
How can we explain the finding of improved survival
following AV repair? Although mitral valve repair
preserves ventriculovalvular continuity and presumably
maintains normal contractile function,14 these same
connections with the ventricle are absent in patients under-
going AV repair. A rigidly fixed aortic annulus, as would
occur following AVR with a stented valve substitute, might
theoretically cause physiologic alterations; however, this is
merely speculative. A more plausible explanation is the
cumulative physiologic effect of living with a degenerating
bioprosthesis. Although primary failure of bioprostheses
may progress rapidly, many patients endure years of expo-
sure to hemodynamically significant valvular regurgitation,
stenosis, or both until structural valve failure is diagnosed
and re-replacement is recommended15 (Figure 1).diovascular Surgery c Volume 148, Number 6 2477
FIGURE 1. Aortic bovine pericardial prosthesis explanted 3 years
following insertion.
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LWill AV repair become more widely available at heart
valve centers? We recently proposed4 that several popula-
tions might preferentially benefit from the more frequent
performance of AV repair. First, young patients with
bicuspid AR had fewer reoperations and longer median
time to repair failure in our experience. Additionally, only
16% of patients with intact AV repair required warfarin
(6% with bicuspid repair alone), which is an attractive
lifestyle advantage to young, active patients and women
of childbearing age. Second, nonelderly patients undergo-
ing other cardiac surgical procedures with concomitant
moderate aortic regurgitation benefit hemodynamically
from aortic annular reduction. Third, those with isolated
AV cusp perforation can often undergo localized pericardial
patch repair, which we have found to be highly effective and
durable. In contrast, the benefits of complex AV repair in
elderly patients with poor cusp tissue quality are less
obvious in comparison to bioprosthetic AVR.
CONCLUSIONS
Contemporary evidence indicates that AV repair for AR
can be performed with very low (<1%) mortality risk at
experienced surgical centers, is as durable as AVR, and2478 The Journal of Thoracic and Cardiovascular Surimproves patient survival when performed before the onset
of left ventricular dilation or dysfunction. Freedom from
anticoagulation and avoidance of exposure to the
cumulative effects of bioprosthetic AVR senescence make
AV repair an attractive option for young patients with
thin, pliable, and mobile aortic cusps; particularly those
with bicuspid AV regurgitation.References
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